The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injections as an add-on therapy for adults with chronic obstructive pulmonary disease (COPD) who continue to struggle ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Dupixent (dupilumab) is tipped to be the market leader ... The IL-4 and IL-13 targeting antibody is administered as a subcutaneous injection every other week after an initial loading dose, and ...

Dupixent (dupilumab) was the first biologic treatment ... Most people are able to give themselves the injection after they learn how. The injection is typically given into a fatty area around ...

Medicare covers medically necessary treatment for eczema. This includes medicated creams and pills, dupilumab (Dupixent) injections, and phototherapy. Original Medicare with a Part D plan or an ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Sanofi has upped its revenue forecasts for the year on the back of strong second quarter results from its new eczema and asthma injection ... said that sales of Dupixent (dupilumab) were up ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

The success of dupilumab, marketed by Sanofi under the name Dupixent, is evident in its remarkable $13 billion global sales achievement in 2024, marking a significant milestone for the company.

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...